Droplet digital polymerase chain reaction (PCR) measurements of circulating tumor DNA (ctDNA) identify patients with stage III melanoma who are at high risk for early recurrence during adjuvant ...

SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for dermatology, hematology, and infectious & inflammatory diseases, announced today ...

Please provide your email address to receive an email when new articles are posted on . Despite the high cure rate of localized cutaneous melanoma, many patients who undergo successful surgical ...

Please provide your email address to receive an email when new articles are posted on . Researchers evaluated a blood test’s ability to predict recurrence in patients with stage 3 melanoma.

Droplet digital PCR measurements of ctDNA may accurately identify patients with melanoma who are at high risk of recurrence. Patients who were ctDNA positive had worse recurrence-free and overall ...

Data come from patients with stage 3 melanoma enrolled in a phase 3 randomized trial and showed that detection of circulating tumor DNA (ctDNA) prior to adjuvant systemic therapy can predict risk of ...

Melanoma survivors may have an increased risk of recurrence, which may heighten fear and worry, but “it’s OK and normal to be worried,” a doctor said. Remaining “vigilant” is important for survivors ...

Results from human trials coupling a new melanoma vaccine with an existing cancer drug showed that, at the three-year mark, the combination treatment reduced the risk of melanoma recurring by 49% and ...

A simple blood test could reveal who is at high risk of skin cancer recurrence after tumor-removal surgery. The test can detect fragments of tumor DNA with a simple blood draw to reveal the lingering ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Early recurrence after adjuvant anti-PD-1/L1 therapy for ...

The median duration of recurrence-free survival was 61.1 and 24.2 months with nivolumab and ipilimumab, respectively, at a minimum follow-up of 107 months. HealthDay News — For patients with resected ...